PD Dr. rer. nat et med. habil. Ernesto Bockamp, is a molecular biologist, immunologist and cancer researcher with many years of experience in generating and analyzing preclinical in vitro and in vivo tumour models.

By reconstructing human diseases in genetically modified mouse models, Dr. Bockamp has generated fundamental insights into hematopoietic stem cells, leukemias and bone formation defects. Dr. Bockamp's current focus is on the development, validation and clinical translation of new cancer immune-therapeutics.

As Chief Scientific Officer (CSO), he founded the company ImmuneNTech GmbH together with Dr. Bernd Lecher and Prof. Dr. Dr. Detlef Schuppan in 2021.

Prof. Dr. Dr. Detlef Schuppan, MD, PhD, is an internist, gastroenterologist, biochemist and immunologist. He has published groundbreaking work in the fields of biochemistry, internal medicine, gastroenterology and hepatology.

Based on this, numerous diagnostic tests and innovative therapeutics could be developed and brought into clinical application. He is PI and co-PI in more than ten national and international research projects with the goal of clinical translation. As part of his clinical outpatient clinic, he plans and leads phase 1-2 clinical trials.

As Chief Medical Officer (CMO) and Chief Scientific Officer (CSO), he founded ImmuneNTech GmbH together with Dr. Bernd Lecher and Dr. Ernesto Bockamp in 2021.